Amit Prasad

Cardiologist, Husband, Passionate about Patient Safety and Quality, Physician Builder for Epic, Biker, Mets Fan! Tweets are my own

[Candel Therapeutics @CandelTx]

Can we turn a tumor into its own vaccine?

Our MOA video explores aglatimagene besadenovec’s biology in localized #ProstateCancer.

Combining intraprostate administration, valacyclovir, and radiotherapy designed to induce immunogenic cell death and stimulate anti-tumor immunity.

[Amit Prasad @AmitPras]

@GhostOptions_ @ripster47 Flow

[Gregg Fonarow MD @gcfmd]

HF Won’t Wait!

Delay ARNI ➡️ 42% ⬆️ risk CV☠️/HF🏨
Delay BB ➡️ 25% ⬆️ risk ☠️
Delay MRA ➡️ 37% ⬆️ risk CV☠️/HF🏨
Delay SGLTi ➡️ 58% ⬆️ risk CV☠️/HF🏨/ER

Unnecessary delays in any one or more of foundational GDMT
➡️ preventable ☠️/🏨

Urgency and intensity needed

[Gregg Fonarow MD @gcfmd]

HFrEF

Compared to 💊💊 therapy, treatment with disease-modifying 💊💊💊💊 therapy in eligible patients

➡️ additional years of survival free from CV ☠️ or HF 🏨

55 yo: 8.3 years
65 yo: 6.3 years
70 yo: 5.2 years
75 yo: 4.1 years
80 yo: 2.7 years

Start ARNI+BB+MRA+SGLT2i now

[American College of Cardiology @ACCinTouch]

In a randomized trial of #heartfailure patients with ejection fraction >40% w/ worsening HF comparing sacubitril/valsartan to valsartan, time-averaged reduction in NT-proBNP was greater in the SV group w/ difference notable within week 1.

More in #JACC: https://t.co/BA5Rko9J8I

[Jeremy S. Pollock @bmorecardiology]

Really nice review of HFpEF in @JACCJournals
Amazing how far we've come in the last 10 years!

https://t.co/hDMpts5TkX

[American College of Cardiology @ACCinTouch]

What are the safety & efficacy outcomes of DOACs & warfarin across the continuous spectrum of kidney function (down to a creatinine clearance [CrCl] of 25 mL/min), w/ a particular focus on patients w/ reduced kidney function?

Learn more: https://t.co/G9WJiLIINi #cvPrev #cvGeri

[American College of Cardiology @ACCinTouch]

Remote monitoring coupled w/ a system of care that engages, informs & empowers patients is essential for effective home management of #heartfailure to control symptoms, avoid hospitalization & ameliorate the patient’s perception of illness. More in #JACC: https://t.co/GAUnc8tR5x

[American College of Cardiology @ACCinTouch]

The results of the FREEDOM COVID trial provide some answers about the role of therapeutic anticoagulation in patients with #COVID19, which has been investigated in several trials. Read the expert analysis to learn more: https://t.co/a6nda85Lpz #cvVTE

[Amit Prasad @AmitPras]

Great book, also.

[Thomas Dayspring @Drlipid]

I second that. His podcasts on lipids are like a lipidology textbook

[Thomas Dayspring @Drlipid]

I second that. His podcasts on lipids are like a lipidology textbook

[Jeff Hsu, MD, PhD @JeffHsuMD]

Full house at the Heart House! @ACCinTouch

We are underway at #ACCAthleticHeart, with Course Chair @DermotPhelanMD opening the ceremonies, which include the Keynote Lecture from #SportsCardio legend, @PaulDThompsonMD

Excited to be back in person with this terrific group 🏃🏻‍♀️ 🏀

[American College of Cardiology @ACCinTouch]

Concurrent use of amiodarone and apixaban/rivaroxaban was associated with higher rates of bleeding hospitalization than with flecainide or sotalol. Read more on risk for bleeding-related hospitalizations with DOACs & amiodarone: https://t.co/VuoQCQa7dz #cvGeri #AFib

[Matthew Budoff MD @BudoffMd]

My most important CAC paper to date just hit:
https://t.co/zRQPfXcyDr
CAC is SECONDARY RISK EQUIVALENT AT score >300
(same cohort, not comparing clinical trial patients to observational studies) @khurramn1 @RonBlankstein @ErinMichos @rblument1

[Amit Prasad @AmitPras]

@CardiacTrials @gcfmd @SJGreene_md Very helpful for providers to know

[Cardiac Trials @CardiacTrials]

Risk of lack of initiation of GDMT in HFrEF, by drug class 👇

📚 courtesy of @gcfmd and @SJGreene_md
#ACCFIT

[Cardiac Trials @CardiacTrials]

Icosapent ethyl in CAD and hypertriglyceridemia? This landmark trial by @BudoffMd and @DLBHATTMD used coronary CT to illustrate the underlying mechanism of icosapent ethyl’s mortality benefit — via regression of unstable coronary plaque. EVAPORATE Trial, EHJ, 2020 ♥️

[Cardiac Trials @CardiacTrials]

DOACs for rheumatic atrial fibrillation? This trial showed INCREASED mortality and stroke/thromboembolism when compared to warfarin, our standard of care. A trial in support of current guidelines for vitamin K antagonism in this population. INVICTUS Trial, NEJM 2022 ♥️ #CardioEd

[Cardiac Trials @CardiacTrials]

SGLT2 Inhibition for HFrEF? Landmark trial showing mortality reduction regardless of diabetes status. Originally a diabetes drug — now with proven cardiovascular and renal protective effects. EMPEROR-Reduced Trial, NEJM 2020 ♥️
#MedEd #MedTwitter

[Eduardo R Argaiz @ArgaizR]

When used as an add-on to Furosemide, SGLT2 was no different than Thiazide for decognestion

However, their effect on serum sodium can help you pick your add-on drug:

If Hyponatremia ➡️ SGLT2
If Hypernatremia ➡️ Thiazide

https://t.co/R5bR4d7yuQ

*acetazolamide up front 😉